In vitro susceptibility of Mycobacterium tuberculosis to a new macrolide antibiotic: RU-28965.
The in vitro susceptibility of Mycobacterium tuberculosis to a new macrolide antibiotic RU-28965, alone and in combination with rifampicin or isoniazid, was studied by the agar dilution method. At a concentration of 4 mg/l, or lower, of RU-28965, 90% of the strains were inhibited. A synergistic effect with both rifampicin and with isoniazid was demonstrated.